Compare KTTA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | HIND |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 15.2M |
| IPO Year | 2021 | 2016 |
| Metric | KTTA | HIND |
|---|---|---|
| Price | $0.44 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 141.8K | 15.8K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | 64.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $486,559.00 | $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3130.37 | 24.43 |
| 52 Week Low | $0.28 | $1.75 |
| 52 Week High | $2.06 | $6.56 |
| Indicator | KTTA | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 46.32 |
| Support Level | $0.43 | $1.86 |
| Resistance Level | $0.52 | $2.31 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 9.01 | 30.42 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.